Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 31 to 35 of 35 results for obinutuzumab

  1. Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma (TA1113)

    Evidence-based recommendations on glofitamab (Columvi) plus gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in adults.

    Technology appraisal guidance
    Published
    3 December 2025
    View recommendations

    Sections for TA1113

  2. Obinutuzumab with CHOP chemotherapy for untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma [ID1021]

    Discontinued Reference number: GID-TA11119

    Technology appraisal guidance
    Discontinued

  3. Idelalisib for treating refractory follicular lymphoma (TA604)

    Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.

    Technology appraisal guidance
    Published
    2 October 2019
    View recommendations

    Sections for TA604

  4. Thousands living with lupus offered hope from twice-yearly infusion

    NICE approves breakthrough combination treatment that restores normal kidney function in almost half of patients with lupus nephritis.

    News
    Last updated
    22 January 2026

  5. NICE recommends new chemotherapy-free treatment option for people with untreated chronic lymphocytic leukaemia

    More than 1,000 people each year will benefit from NICE's recommendation.

    News
    Last updated
    15 January 2024